Assessing Tenapanor as a Treatment of CF-related Constipation. | MicrobiomeTrials← Back to trialsNCT06810167
Assessing Tenapanor as a Treatment of CF-related Constipation.
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2025-06-01Est. Completion: 2026-06-15
Enrollment target: 25 participants Locations- Massachusetts General Hospital, Boston, Massachusetts, United States
Other microbiome trials you might be interested in
Cystic Fibrosis
This study will evaluate the long-term safety, efficacy and pharmacodynamics of ELX/TEZ/IVA in participants with cystic …
Innsbruck, AustriaEst. completion Apr 6, 2027
Cystic FibrosisPulmonary FibrosisTuberous SclerosisAsthmaPulmonary Sarcoidosis
This study is designed to evaluate the genetics involved in the development of lung disease by surveying genes involved …
Bethesda, United States
The purpose of Parts D and E of this Phase 1 study are to evaluate the safety, tolerability, and pharmacokinetics of mul…
Brisbane, AustraliaCompleted Mar 23, 2026